|
Index of reports
> Cases resulting in hospitalization (12)
Below is the selection of adverse event reports related to Estrace (Estradiol Vaginal) that includes cases resulting in hospitalization.
Adverse event in female receiving Estrace (Estradiol Vaginal)
Reported by a consumer/non-health professional from United States on 2007-10-31
Patient: female, weighing 79.5 kg (174.8 pounds)
Adverse reactions / side effects: Ovarian Cancer Metastatic
Adverse event resulted in: death, hospitalization
Suspect drug(s):
Estrace
Estradiol
Dosage: unknown
Administration route: Oral
Indication: Menopausal Symptoms Prophylaxis
Start date: 1989-01-01
Estrogens Esterified / Methyltestosterone
Premarin
Dosage: unspecified
Administration route: Oral
Start date: 1992-01-01
End date: 2004-01-01
Other drugs received by patient: Xanax
Adverse event in female receiving Estrace (Estradiol Vaginal)
Reported by a consumer/non-health professional from United States on 2007-10-30
Patient: female, weighing 59.0 kg (129.8 pounds)
Adverse reactions / side effects: Breast Cancer Metastatic
Adverse event resulted in: hospitalization
Suspect drug(s):
Estrace
Premarin
Dosage: unknown
Indication: Oestrogen Replacement Therapy
Start date: 1994-01-01
End date: 1996-01-01
Prempro
Dosage: unknown
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1996-01-01
End date: 2002-01-01
Provera
Dosage: unknown
Indication: Hormone Replacement Therapy
Start date: 1996-01-01
End date: 2002-01-01
Adverse event in female receiving Estrace (Estradiol Vaginal)
Reported by a consumer/non-health professional from United States on 2007-10-30
Patient: female
Adverse reactions / side effects: Breast Cancer Metastatic
Adverse event resulted in: hospitalization
Suspect drug(s):
Estrace
Estradiol
Medroxyprogesterone Acetate
Premarin
Prempro
Provera
Adverse event in 62 year old female receiving Estrace (Estradiol Vaginal)
Reported by a individual with unspecified qualification from United States on 2007-07-02
Patient: 62 year old female, weighing 99.8 kg (219.5 pounds)
Adverse reactions / side effects: Polyp Colorectal, Mammogram Abnormal, Fibrocystic Breast Disease, Intervertebral Disc Disorder, Postmenopausal Haemorrhage, Breast Microcalcification, Blood Cholesterol Increased, Benign Breast Neoplasm, Breast Hyperplasia, Breast Cancer, Tonsillectomy, Abscess Drainage, Mastitis, Radiotherapy, Malignant Breast Lump Removal, Appendicitis, Anal Fissure, Haematochezia, Hysterectomy, Uterine Dilation and Curettage, Colonoscopy Abnormal
Adverse event resulted in: hospitalization
Suspect drug(s):
Cycrin
Start date: 1999-01-01
Estrace
Dosage: unk, qhs
Start date: 1999-01-01
Estraderm
Start date: 1989-01-01
Estratest
Start date: 1990-01-01
End date: 1999-01-01
Premarin
Dosage: 0.625 unk, unk
Administration route: Oral
Start date: 1989-01-01
Prempro
Indication: Menopause
Start date: 1999-04-01
End date: 2002-04-01
Provera
Dosage: 10 mg, unk
Start date: 1989-01-01
Other drugs received by patient: Steroids NOS; Oxygen Therapy; Lotrel; Cardizem
Adverse event in 67 year old female receiving Estrace (Estradiol Vaginal)
Reported by a consumer/non-health professional from United States on 2007-05-30
Patient: 67 year old female, weighing 74.8 kg (164.6 pounds)
Adverse reactions / side effects: Colon Cancer, Small Intestine Carcinoma Stage IV, Small Intestine Carcinoma Metastatic
Adverse event resulted in: hospitalization
Suspect drug(s):
Estrace (Estradiol Vaginal)
Other drugs received by patient: Synthroid; Allegra / 01314201 / (Fexofenadine); Inderal / 00030001 / (Propranolol)
Adverse event in 60 year old female receiving Estrace (Estradiol Vaginal)
Reported by a individual with unspecified qualification from United States on 2007-04-05
Patient: 60 year old female, weighing 68.0 kg (149.7 pounds)
Adverse reactions / side effects: Thrombosis, Therapeutic Procedure, Pulmonary Embolism, Chronic Obstructive Pulmonary Disease, Cyst Aspiration, Breast Cyst, Psychiatric Symptom, Proteinuria, Breast Microcalcification, Irritable Bowel Syndrome, Vaginal Burning Sensation, Benign Breast Neoplasm, Chondropathy, Pneumonia, Dysphagia, Pain in Extremity, Essential Tremor, Breast Mass, Osteopenia, Sacroiliitis, Lung Hyperinflation, Occult Blood Positive, Pulmonary Function Test Abnormal, Chondrocalcinosis, Rhonchi, Mental Disorder, Aortic Valve Disease, Vertigo Positional, Post Procedural Complication, Pain, Gastric Mucosal Hypertrophy, Carpal Tunnel Decompression, Urinary Tract Disorder, Ventricular Hypertrophy, Interstitial Lung Disease, Dizziness, Joint Arthroplasty, Injury, Sinusitis, Emphysema, Mitral Valve Disease, Dyspnoea, Calcinosis, Cystitis, Echocardiogram Abnormal, Atrophic Vulvovaginitis, Haematochezia, Gastrointestinal Pain, Diarrhoea, Blood Potassium Decreased, Pulmonary Thrombosis, Spinal Osteoarthritis, Lung Infiltration, Arthritis
Adverse event resulted in: hospitalization
Suspect drug(s):
Amen
Dosage: 10 mg, unk
Indication: Hormone Replacement Therapy
Start date: 1992-10-01
End date: 1996-08-01
Estrace
Dosage: 2 mg, qd
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1994-10-01
End date: 1994-11-01
Estraderm
Dosage: 1 mg, unk
Indication: Hormone Replacement Therapy
Start date: 1996-01-01
End date: 1996-10-01
MPA
Dosage: 10mg/5mg, unk
Indication: Hormone Replacement Therapy
Start date: 1994-01-01
End date: 1996-11-01
Ovcon-35
Premarin
Dosage: 1.25mg/2.5mg
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1992-01-01
End date: 1996-08-01
Premarin
Dosage: unk, unk
Indication: Atrophic Vulvovaginitis
Prempro
Dosage: 2.5mg/0.625mg
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1996-11-01
End date: 2001-01-01
Other drugs received by patient: Vioxx
Adverse event in 61 year old female receiving Estrace (Estradiol Vaginal)
Reported by a individual with unspecified qualification from United States on 2007-03-28
Patient: 61 year old female, weighing 89.8 kg (197.5 pounds)
Adverse reactions / side effects: Breast Cancer, Biopsy Breast Abnormal, Breast Mass, Malignant Breast Lump Removal, Progesterone Receptor Assay Positive, Haemangioma of Liver, Limb Discomfort, Oedema Peripheral, Depression, Lymphadenectomy, Knee Arthroplasty, Oestrogen Receptor Assay Positive, Lung Infiltration
Adverse event resulted in: hospitalization
Suspect drug(s):
Estrace
Indication: Night Sweats
Estratab
Dosage: 0.625 mg, qd
Indication: Night Sweats
Estropipate
Dosage: 1 mg, unk
Indication: Amnesia
Premarin
Dosage: 0.625 mg, unk
Indication: Affective Disorder
Prempro
Indication: Amnesia
Provera
Dosage: 2.5 mg, qd
Indication: Hormone Replacement Therapy
Vivelle
Indication: Hormone Replacement Therapy
Vivelle-DOT
Indication: Hormone Replacement Therapy
Other drugs received by patient: Fish OIL; Alprazolam; Celebrex
Adverse event in 59 year old female receiving Estrace (Estradiol Vaginal)
Reported by a individual with unspecified qualification from United States on 2007-03-27
Patient: 59 year old female, weighing 96.1 kg (211.5 pounds)
Adverse reactions / side effects: Abdominal Pain, Abdominal Operation, Urinary Incontinence, Cervix Disorder, Incisional Hernia, Upper Respiratory Tract Infection, Central Venous Catheterisation, Postmenopausal Haemorrhage, Colostomy, Tendonitis, Rectal Prolapse, Breast Cancer, Enterostomy, Pelvic Abscess, Bursitis, non-Cardiac Chest Pain, Menopause, Cholelithiasis, Emotional Distress, Diverticulum, Vaginal Infection, Uterine Haemorrhage, Oophorectomy, Bladder Prolapse, Post Procedural Complication, Pain, Pelvic Pain, Cardiac Valve Disease, Hypercholesterolaemia, Ovarian Cystectomy, Fibrocystic Breast Disease, Basal Cell Carcinoma, Haemorrhagic Ovarian Cyst, Injury, Renal Failure Acute, Cataract, Mass, Urinary Tract Infection, Synovitis, Hernia, Tubal Ligation, Osteoarthritis, Adhesiolysis, Small Intestinal Resection, Radical Mastectomy, Uterine Prolapse Repair, Hypertension, Leukopenia, Abdominal Adhesions
Adverse event resulted in: hospitalization
Suspect drug(s):
Estrace
Dosage: 1 mg, qd
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1994-05-23
Estrace Vaginal Cream
Dosage: 2 g oncde per week
Indication: Menopausal Symptoms
Start date: 1994-04-27
Estrace Vaginal Cream
Dosage: 2 g once per week
Start date: 1994-05-23
Estraderm
Dosage: 0.1 mg, unk
Start date: 1999-08-02
Loestrin 1.5 / 30
Dosage: 1.5 mg, unk
Start date: 1994-09-08
Premarin
Dosage: 0.625 mg, qd
Administration route: Oral
Indication: Menopausal Symptoms
Start date: 1984-09-26
End date: 1997-10-01
Prempro
Dosage: .625/5 mg
Administration route: Oral
Indication: Menopausal Symptoms
Start date: 1997-06-25
End date: 2001-12-02
Provera
Dosage: 2.5 mg, qd
Administration route: Oral
Indication: Menopausal Symptoms
Start date: 1994-05-23
Provera
Dosage: 5 mg, qd
Administration route: Oral
Start date: 1996-01-02
End date: 1997-10-01
Other drugs received by patient: Prilosec; Avalide
Adverse event in 57 year old female receiving Estrace (Estradiol Vaginal)
Reported by a physician from United States on 2007-03-27
Patient: 57 year old female, weighing 70.3 kg (154.6 pounds)
Adverse reactions / side effects: Diabetes Mellitus, Hypoglycaemia, Breast Cancer in Situ, Macular Degeneration, Mammogram Abnormal, Hyperventilation, Oesophageal Dilatation, Irritable Bowel Syndrome, Bone Density Decreased, Ventricular Extrasystoles, Renal Stone Removal, Arrhythmia Supraventricular, Hiatus Hernia, Haematuria, Anaemia, Hypotension, Glucose Tolerance Impaired, Diverticulum, Otitis Media, Cholecystectomy, Nerve Injury, Chills, Weight Increased, Fatigue, Chronic Sinusitis, Adrenal Insufficiency, Dizziness, Oestrogen Receptor Assay Positive, Cholecystitis, Gastrooesophageal Reflux Disease, Somatisation Disorder, Atrial Fibrillation, Progesterone Receptor Assay Positive, Anxiety, Syncope, Asthenia
Adverse event resulted in: hospitalization
Suspect drug(s):
Estrace
Indication: Menopausal Symptoms
Start date: 1990-01-01
Estraderm
Administration route: Topical
Indication: Menopausal Symptoms
Start date: 1990-01-01
Ogen
Indication: Menopausal Symptoms
Start date: 1989-01-01
Premarin
Indication: Menopausal Symptoms
Start date: 1975-01-01
End date: 1994-01-01
Prempro
Dosage: unk, unk
Indication: Menopausal Symptoms
Start date: 1975-01-01
End date: 1991-01-01
Other drugs received by patient: Benadryl
Adverse event in 58 year old female receiving Estrace (Estradiol Vaginal)
Reported by a physician from United States on 2007-03-15
Patient: 58 year old female
Adverse reactions / side effects: Pulmonary Hypertension, Biopsy Breast Abnormal, Diabetes Mellitus, Dilatation Ventricular, Tricuspid Valve Incompetence, Treatment Noncompliance, Surgery, Atrial Hypertrophy, Oedema Peripheral, Breast Hyperplasia, Echocardiogram, Back Pain, Supraventricular Tachycardia, Breast Cancer Female, Cholelithiasis, Ventricular Dysfunction, Cholecystectomy, Homicidal Ideation, Scan Myocardial Perfusion Abnormal, Head Injury, Breast Cancer Stage IV, Pain, Hemiparesis, Fall, Fatigue, Fibrocystic Breast Disease, Coronary Artery Bypass, Dizziness, Lymphoedema, Atrial Flutter, Urinary Tract Infection, Atrial Fibrillation, Cerebrovascular Accident, Cardiac Pacemaker Insertion, Arthralgia, Mitral Valve Incompetence, Infarction
Adverse event resulted in: hospitalization
Suspect drug(s):
Curretab
Indication: Hormone Replacement Therapy
Start date: 1985-01-01
End date: 1995-01-01
Cycrin
Indication: Hormone Replacement Therapy
Start date: 1985-01-01
End date: 1995-01-01
Estrace
Indication: Hormone Replacement Therapy
Start date: 1985-01-01
End date: 1995-01-01
Estratest
Indication: Hormone Replacement Therapy
Start date: 1985-01-01
End date: 1995-01-01
MPA
Indication: Hormone Replacement Therapy
Start date: 1985-01-01
End date: 1995-01-01
Premarin
Dosage: 10 mg, unk
Administration route: Oral
End date: 1996-08-01
Prempro
Dosage: 0.625/25 mg, unk
Indication: Hormone Replacement Therapy
Start date: 1996-08-01
End date: 2002-08-01
Provera
Dosage: 0.625 mg, unk
Administration route: Oral
End date: 1996-08-01
Vivelle
Indication: Hormone Replacement Therapy
Start date: 1985-01-01
End date: 1995-01-01
Adverse event in 55 year old female receiving Estrace (Estradiol Vaginal)
Reported by a individual with unspecified qualification from United States on 2007-03-05
Patient: 55 year old female
Adverse reactions / side effects: Vascular Bypass Graft, Stent Placement, Tachycardia, Headache, Fatigue, Thrombophlebitis Superficial, Palpitations, Oedema Peripheral, Chest Pain, Bundle Branch Block Bilateral, Depression, Myocardial Infarction, Dyspnoea, Supraventricular Tachycardia, Coronary Artery Disease, Percutaneous Coronary Intervention, Catheterisation Cardiac, Visual Disturbance, Presyncope, Cardiac Ablation, Deep Vein Thrombosis
Adverse event resulted in: hospitalization
Suspect drug(s):
Estrace
Estraderm
Indication: Hormone Replacement Therapy
Prempro
Administration route: Oral
Start date: 1991-01-01
End date: 1998-01-01
Provera
Dosage: unk, unk
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1990-01-01
End date: 1991-01-01
Other drugs received by patient: Crestor; Tricor; Norvasc; Glucophage; Metoprolol Tartrate; Acetylsalicylic Acid SRT; Pravachol; Plavix; Zetia
Adverse event in 57 year old female receiving Estrace (Estradiol Vaginal)
Reported by a individual with unspecified qualification from United States on 2007-03-01
Patient: 57 year old female, weighing 56.7 kg (124.7 pounds)
Adverse reactions / side effects: Breast Cancer, Back Pain, Pain in Extremity, Angina Pectoris, Osteoporosis, Musculoskeletal Pain, Tachycardia, Radiotherapy, Lumbar Radiculopathy, Cervical Conisation, Smear Cervix Abnormal, Catheterisation Cardiac, Palpitations, Intervertebral Disc Disorder, Mastectomy, Spinal Osteoarthritis, Gastrooesophageal Reflux Disease
Adverse event resulted in: hospitalization
Suspect drug(s):
Estrace
Indication: Hormone Replacement Therapy
Start date: 1993-08-12
End date: 1993-09-14
Estraderm
Dosage: 0.05 mg patch
Indication: Hormone Replacement Therapy
Start date: 1993-09-14
End date: 1994-08-08
Premarin
Dosage: 0.3-0.625mg
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1989-06-06
End date: 1993-08-12
Provera
Dosage: 2.5-10mg
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1989-06-06
End date: 1994-09-14
Other drugs received by patient: Maxzide; Atenolol; Norethindrone; Tamoxifen Citrate
|
